多领域干预和/或ω-3 对淀粉样蛋白状态正常的非痴呆老年患者的影响。
Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status.
机构信息
INSERM UMR 1027, Toulouse, France; University of Toulouse III, Toulouse, France; Gérontopôle, Department of Geriatrics, Toulouse (University Hospital) CHU, Purpan University Hospital, Toulouse, France.
Department of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, France; Toulouse NeuroImaging Center, University of Toulouse, INSERM, UPS, Toulouse, France.
出版信息
Alzheimers Dement. 2019 Nov;15(11):1392-1401. doi: 10.1016/j.jalz.2019.07.008. Epub 2019 Sep 23.
INTRODUCTION
The Multidomain Alzheimer Preventive Trial (MAPT) assessed the efficacy of omega-3 fatty acid supplementation, a multidomain intervention (MI), or a combination of both on cognition. Impact according to cerebral amyloid status was evaluated by PET scan.
METHODS
Participants were nondemented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. The primary outcome was a change from baseline in 36 months measured with a cognitive composite Z score.
RESULTS
No effect was observed on cognition in the negative amyloid group (n = 167). In the positive amyloid group (n = 102), we observed a difference of 0.708 and 0.471 in the cognitive composite score between the MI plus omega-3 fatty acid group, the MI alone group, and the placebo group, respectively.
DISCUSSION
MI alone or in combination with omega-3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status.
TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT01513252.
简介
多领域阿尔茨海默病预防试验（MAPT）评估了ω-3 脂肪酸补充剂、多领域干预（MI）或两者联合对认知的疗效。通过 PET 扫描评估根据脑淀粉样蛋白状态的影响。
方法
参与者为非痴呆且有记忆障碍、一项日常活动工具性能力受限或步态缓慢。主要结局是在 36 个月时用认知综合 Z 评分从基线测量的变化。
结果
在阴性淀粉样蛋白组（n=167）中，认知无影响。在阳性淀粉样蛋白组（n=102）中，我们观察到 MI 加 ω-3 脂肪酸组、MI 组和安慰剂组的认知综合评分分别相差 0.708 和 0.471。
讨论
MI 单独或联合 ω-3 脂肪酸与阳性淀粉样蛋白状态受试者的主要认知结局改善相关。
试验注册
ClinicalTrials.gov 标识符：NCT01513252。
Zotero 插件